Lantheus Completes Sale of SPECT Business to SHINE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Lantheus Holdings completed the previously announced sale of its single photon emission computed tomography business to SHINE Technologies. Under the terms of the agreement, SHINE has acquired Lantheus' SPECT business, including its diagnostic agents, the portion of the North Billerica, Massachusetts campus that manufactures Lantheus' SPECT products, and the SPECT-related Canadian operations. With the SPECT divestiture finalized, Lantheus will focus on its growing commercial portfolio of PET radiodiagnostics and microbubbles, while also advancing its pipeline of radiopharmaceuticals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LNTH
Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 82.17 USD with a low forecast of 70.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 66.680
Low
70.00
Averages
82.17
High
105.00
Current: 66.680
Low
70.00
Averages
82.17
High
105.00
About LNTH
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. The Company's product categories include Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Others. The Company's Radiopharmaceutical Oncology products help healthcare professionals (HCPs) find, fight and follow cancer. The Company's Precision Diagnostic products assist HCPs to find and follow diseases. Its Strategic Partnerships include biomarkers and digital solutions in support of its partners’ therapeutic development, out-licensing agreements for non-core assets and optimization of its assets geographically. The Company's commercial products are used by cardiologists, internal medicine physicians, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists working in a variety of clinical settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iovance and Others Face Shareholder Lawsuits Seeking Governance Reforms
- Shareholder Lawsuit Background: Iovance Biotherapeutics is facing a securities class action lawsuit from shareholders alleging that it failed to disclose significant misleading information regarding the commercial demand and revenue potential of its lead therapy, Amtagvi, resulting in investor losses.
- Governance Reform Opportunity: Shareholders who held Iovance shares continuously since before May 9, 2024, may seek governance reforms related to internal controls, transparency, and executive oversight, with successful claimants potentially eligible for incentive awards subject to court approval.
- Nutex Health Allegations: Nutex Health is similarly facing shareholder lawsuits, accused of overstating revenue from arbitration-related claims and failing to disclose material weaknesses in internal accounting controls, which led to financial results not being prepared in accordance with GAAP, impacting investor confidence.
- Molina Healthcare Issues: Molina Healthcare has also been accused of making misleading statements regarding medical cost trends and financial outlook, failing to disclose that medical cost pressures were materially higher than represented, potentially leading to governance reform opportunities for its shareholders.
Continue Reading
Lantheus Sells SPECT Business to SHINE, Focuses on PET Radiodiagnostics
- Business Sale: Lantheus has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, which includes diagnostic agents like TechneLite® and NEUROLITE®, marking a strategic shift for the company.
- Focus on Innovation: Post-sale, Lantheus will concentrate on its expanding portfolio of PET radiodiagnostics and microbubbles, which is expected to enhance its competitiveness and innovation in the radiopharmaceutical market.
- Advisory Support: Solomon Partners Securities acted as the financial advisor for Lantheus in this transaction, while Foley Hoag LLP and Ropes & Gray LLP provided legal support, ensuring a smooth transaction process.
- Market Outlook: By divesting its SPECT business, Lantheus aims to optimize resource allocation and focus on its high-growth potential PET product line to meet increasing market demand and improve patient treatment outcomes.
Continue Reading